Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
|September 2018 Strategy Update Webcast and Presentation|
|Second Quarter 2018 Press Release|
|Second Quarter 2018 10Q|
|IPO Final Prospectus|
OBLN (Common Stock) $2.16 - 0.04 (1.82%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Daina Schmidt Joins Obalon Therapeutics As Vice President, Marketing
FDA Grants PMA-S Approval for Obalon Touch™ Inflation System
Obalon to Host Corporate Strategy Update Call with Investors and Analysts on September 10, 2018
Obalon Therapeutics Announces Closing of $10 Million Private Placement
|There are currently no events scheduled.|